Patent intelligence · US
US 8962824
Composition of novel carbohydrate drug for treatment of human diseases
Composition of novel carbohydrate drug for treatment of human diseases
Patent details — US 8962824
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 24, 2015
- Expiration
- Feb 19, 2035
- Applicant
- GALECTIN THERAPEUTICS, INC.
- Claims
- 30
- CPC classes
- A61K, A61K31/70, A61K31/715, A61K31/738
Quick answer
US 8962824 (Composition of novel carbohydrate drug for treatment of human diseases) is held by GALECTIN THERAPEUTICS, INC.. Status: granted. Granted Feb 24, 2015. Expires Feb 19, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- GALECTIN THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 30
- CPC classes
- A61K, A61K31/70, A61K31/715, A61K31/738, A61K45/06, A61P
More from GALECTIN THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12377102
Compounds for the prevention and treatment of medical disorders and uses thereof
granted -
US 11583530
Compounds for the prevention and treatment of medical disorders and uses thereof
granted -
US 11576924
Compounds for the prevention and treatment of diseases and the use thereof
granted -
US 11413303
Methods for treatment of arthritis
granted -
US 10799525
Composition of novel carbohydrate drug for treatment of human diseases
granted -
US 10744154
Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
granted -
US 10420793
Composition of novel carbohydrate drug for treatment of human diseases
granted -
US 9974802
Composition of novel carbohydrate drug for treatment of human diseases
granted
Frequently asked questions
What is US patent 8962824?
US 8962824 (Composition of novel carbohydrate drug for treatment of human diseases) is held by GALECTIN THERAPEUTICS, INC.. Status: granted. Granted Feb 24, 2015. Expires Feb 19, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8962824?
GALECTIN THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 20 pharmaceutical patents for this assignee.
When does US 8962824 expire?
Our index shows an expiration date of Feb 19, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.